Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.

ABSTRACT:

Opinion statement

The therapeutic armamentarium has significantly expanded since the approval of various CD19-targeting chimeric antigen receptor T cell (CAR-T) therapies in non-Hodgkin lymphoma (NHL). These CAR-Ts are patient-specific and require a complex, resource, and time-consuming process. While this appears promising, autologous CAR-Ts are limited due to the lack of accessibility, manufacturing delays, and variable product quality. To overcome these, allogeneic (allo) CARs from healthy donors appear appealing. These can be immediately available as "off the shelf" ready-to-use products of standardized and superior quality exempt from the effects of an immunosuppressive tumor microenvironment and prior treatments, and potentially with lower healthcare utilization using industr

SUBMITTER: Khurana A 

PROVIDER: S-EPMC8873350 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature